1 5082 146 PI3KDELTA/GAMMA INHIBITION PROMOTES HUMAN CART CELL EPIGENETIC AND METABOLIC REPROGRAMMING TO ENHANCE ANTITUMOR CYTOTOXICITY. CURRENT LIMITATIONS IN USING CHIMERIC ANTIGEN RECEPTOR T(CART) CELLS TO TREAT PATIENTS WITH HEMATOLOGICAL CANCERS INCLUDE LIMITED EXPANSION AND PERSISTENCE IN VIVO THAT CONTRIBUTE TO CANCER RELAPSE. PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) HAVE TERMINALLY DIFFERENTIATED T CELLS WITH AN EXHAUSTED PHENOTYPE AND EXPERIENCE LOW COMPLETE RESPONSE RATES AFTER AUTOLOGOUS CART THERAPY. BECAUSE PI3K INHIBITOR THERAPY IS ASSOCIATED WITH THE DEVELOPMENT OF T-CELL-MEDIATED AUTOIMMUNITY, WE STUDIED THE EFFECTS OF INHIBITING THE PI3KDELTA AND PI3KGAMMA ISOFORMS DURING THE MANUFACTURE OF CART CELLS PREPARED FROM PATIENTS WITH CLL. DUAL PI3KDELTA/GAMMA INHIBITION NORMALIZED CD4/CD8 RATIOS AND MAXIMIZED THE NUMBER OF CD8+ T-STEM CELL MEMORY, NAIVE, AND CENTRAL MEMORY T-CELLS WITH DOSE-DEPENDENT DECREASES IN EXPRESSION OF THE TIM-3 EXHAUSTION MARKER. CART CELLS MANUFACTURED WITH DUVELISIB (DUV-CART CELLS) SHOWED SIGNIFICANTLY INCREASED IN VITRO CYTOTOXICITY AGAINST CD19+ CLL TARGETS CAUSED BY INCREASED FREQUENCIES OF CD8+ CART CELLS. DUV-CART CELLS HAD INCREASED EXPRESSION OF THE MITOCHONDRIAL FUSION PROTEIN MFN2, WITH AN ASSOCIATED INCREASE IN THE RELATIVE CONTENT OF MITOCHONDRIA. DUV-CART CELLS EXHIBITED INCREASED SIRT1 AND TCF1/7 EXPRESSION, WHICH CORRELATED WITH EPIGENETIC REPROGRAMING OF DUV-CART CELLS TOWARD STEM-LIKE PROPERTIES. AFTER TRANSFER TO NOG MICE ENGRAFTED WITH A HUMAN CLL CELL LINE, DUV-CART CELLS EXPRESSING EITHER A CD28 OR 41BB COSTIMULATORY DOMAIN DEMONSTRATED SIGNIFICANTLY INCREASED IN VIVO EXPANSION OF CD8+ CART CELLS, FASTER ELIMINATION OF CLL, AND LONGER PERSISTENCE. DUV-CART CELLS SIGNIFICANTLY ENHANCED SURVIVAL OF CLL-BEARING MICE COMPARED WITH CONVENTIONALLY MANUFACTURED CART CELLS. IN SUMMARY, EXPOSURE OF CART TO A PI3KDELTA/GAMMA INHIBITOR DURING MANUFACTURING ENRICHED THE CART PRODUCT FOR CD8+ CART CELLS WITH STEM-LIKE QUALITIES AND ENHANCED EFFICACY IN ELIMINATING CLL IN VIVO. 2022 2 5081 35 PI3KDELTA COORDINATES TRANSCRIPTIONAL, CHROMATIN, AND METABOLIC CHANGES TO PROMOTE EFFECTOR CD8(+) T CELLS AT THE EXPENSE OF CENTRAL MEMORY. PATIENTS WITH ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE DELTA (PI3KDELTA) SYNDROME (APDS) PRESENT WITH SINOPULMONARY INFECTIONS, LYMPHADENOPATHY, AND CYTOMEGALVIRUS (CMV) AND/OR EPSTEIN-BARR VIRUS (EBV) VIREMIA, YET WHY PATIENTS FAIL TO CLEAR CERTAIN CHRONIC VIRAL INFECTIONS REMAINS INCOMPLETELY UNDERSTOOD. USING PATIENT SAMPLES AND A MOUSE MODEL (PIK3CD(E1020K/+) MICE), WE DEMONSTRATE THAT, UPON ACTIVATION, PIK3CD(E1020K/+) CD8(+) T CELLS EXHIBIT EXAGGERATED FEATURES OF EFFECTOR POPULATIONS BOTH IN VITRO AND AFTER VIRAL INFECTION THAT ARE ASSOCIATED WITH INCREASED FAS-MEDIATED APOPTOSIS DUE TO SUSTAINED FOXO1 PHOSPHORYLATION AND FASL DEREPRESSION, ENHANCED MTORC1 AND C-MYC SIGNATURES, METABOLIC PERTURBATIONS, AND AN ALTERED CHROMATIN LANDSCAPE. CONVERSELY, PIK3CD(E1020K/+) CD8(+) CELLS FAIL TO SUSTAIN EXPRESSION OF PROTEINS CRITICAL FOR CENTRAL MEMORY, INCLUDING TCF1. STRIKINGLY, ACTIVATED PIK3CD(E1020K/+) CD8(+) CELLS EXHIBIT ALTERED TRANSCRIPTIONAL AND EPIGENETIC CIRCUITS CHARACTERIZED BY PRONOUNCED INTERLEUKIN-2 (IL-2)/STAT5 SIGNATURES AND HEIGHTENED IL-2 RESPONSES THAT PREVENT DIFFERENTIATION TO MEMORY-LIKE CELLS IN IL-15. OUR DATA POSITION PI3KDELTA AS INTEGRATING MULTIPLE SIGNALING NODES THAT PROMOTE CD8(+) T CELL EFFECTOR DIFFERENTIATION, PROVIDING INSIGHT INTO PHENOTYPES OF PATIENTS WITH APDS. 2021 3 1763 32 EARLY TRANSCRIPTIONAL AND EPIGENETIC DIVERGENCE OF CD8+ T CELLS RESPONDING TO ACUTE VERSUS CHRONIC INFECTION. DURING A MICROBIAL INFECTION, RESPONDING CD8+ T CELLS GIVE RISE TO EFFECTOR CELLS THAT PROVIDE ACUTE HOST DEFENSE AND MEMORY CELLS THAT PROVIDE SUSTAINED PROTECTION. AN ALTERNATIVE OUTCOME IS EXHAUSTION, A STATE OF T CELL DYSFUNCTION THAT OCCURS IN THE CONTEXT OF CHRONIC INFECTIONS AND CANCER. ALTHOUGH IT IS EVIDENT THAT EXHAUSTED CD8+ T (TEX) CELLS ARE PHENOTYPICALLY AND MOLECULARLY DISTINCT FROM EFFECTOR AND MEMORY CD8+ T CELLS, THE FACTORS REGULATING THE EARLIEST EVENTS IN THE DIFFERENTIATION PROCESS OF TEX CELLS REMAIN INCOMPLETELY UNDERSTOOD. HERE, WE PERFORMED SINGLE-CELL RNA-SEQUENCING AND SINGLE-CELL ATAC-SEQUENCING OF CD8+ T CELLS RESPONDING TO LCMV-ARMSTRONG (LCMV-ARM) OR LCMV-CLONE 13 (LCMV-CL13), WHICH RESULT IN ACUTE OR CHRONIC INFECTIONS, RESPECTIVELY. COMPARED TO CD8+ T CELLS THAT HAD UNDERGONE THEIR FIRST DIVISION IN RESPONSE TO LCMV-ARM (DIV1ARM) CELLS, CD8+ T CELLS THAT HAD UNDERGONE THEIR FIRST DIVISION IN RESPONSE TO LCMV-CL13 (DIV1CL13) EXPRESSED HIGHER LEVELS OF GENES ENCODING TRANSCRIPTION FACTORS PREVIOUSLY ASSOCIATED WITH EXHAUSTION, ALONG WITH HIGHER LEVELS OF EZH2, THE CATALYTIC COMPONENT OF THE POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) COMPLEX, WHICH MEDIATES EPIGENETIC SILENCING. MODULATION OF EZH2 RESULTED IN ALTERED EXPRESSION OF EXHAUSTION-ASSOCIATED MOLECULES BY CD8+ T CELLS RESPONDING TO LCMV-CL13, THOUGH THE SPECIFIC CELLULAR AND INFECTIOUS CONTEXTS, RATHER THAN SIMPLY THE LEVEL OF EZH2 EXPRESSION, LIKELY DETERMINE THE EVENTUAL OUTCOME. TAKEN TOGETHER, THESE FINDINGS SUGGEST THAT THE DIFFERENTIATION PATHS OF CD8+ T CELLS RESPONDING TO ACUTE VERSUS CHRONIC INFECTIONS MAY DIVERGE EARLIER THAN PREVIOUSLY APPRECIATED. 2023 4 4866 37 ORTHOGONAL CRISPR SCREENS TO IDENTIFY TRANSCRIPTIONAL AND EPIGENETIC REGULATORS OF HUMAN CD8 T CELL FUNCTION. THE CLINICAL RESPONSE TO ADOPTIVE T CELL THERAPIES IS STRONGLY ASSOCIATED WITH TRANSCRIPTIONAL AND EPIGENETIC STATE. THUS, TECHNOLOGIES TO DISCOVER REGULATORS OF T CELL GENE NETWORKS AND THEIR CORRESPONDING PHENOTYPES HAVE GREAT POTENTIAL TO IMPROVE THE EFFICACY OF T CELL THERAPIES. WE DEVELOPED POOLED CRISPR SCREENING APPROACHES WITH COMPACT EPIGENOME EDITORS TO SYSTEMATICALLY PROFILE THE EFFECTS OF ACTIVATION AND REPRESSION OF 120 TRANSCRIPTION FACTORS AND EPIGENETIC MODIFIERS ON HUMAN CD8+ T CELL STATE. THESE SCREENS NOMINATED KNOWN AND NOVEL REGULATORS OF T CELL PHENOTYPES WITH BATF3 EMERGING AS A HIGH CONFIDENCE GENE IN BOTH SCREENS. WE FOUND THAT BATF3 OVEREXPRESSION PROMOTED SPECIFIC FEATURES OF MEMORY T CELLS SUCH AS INCREASED IL7R EXPRESSION AND GLYCOLYTIC CAPACITY, WHILE ATTENUATING GENE PROGRAMS ASSOCIATED WITH CYTOTOXICITY, REGULATORY T CELL FUNCTION, AND T CELL EXHAUSTION. IN THE CONTEXT OF CHRONIC ANTIGEN STIMULATION, BATF3 OVEREXPRESSION COUNTERED PHENOTYPIC AND EPIGENETIC SIGNATURES OF T CELL EXHAUSTION. CAR T CELLS OVEREXPRESSING BATF3 SIGNIFICANTLY OUTPERFORMED CONTROL CAR T CELLS IN BOTH IN VITRO AND IN VIVO TUMOR MODELS. MOREOVER, WE FOUND THAT BATF3 PROGRAMMED A TRANSCRIPTIONAL PROFILE THAT CORRELATED WITH POSITIVE CLINICAL RESPONSE TO ADOPTIVE T CELL THERAPY. FINALLY, WE PERFORMED CRISPR KNOCKOUT SCREENS WITH AND WITHOUT BATF3 OVEREXPRESSION TO DEFINE CO-FACTORS AND DOWNSTREAM FACTORS OF BATF3, AS WELL AS OTHER THERAPEUTIC TARGETS. THESE SCREENS POINTED TO A MODEL WHERE BATF3 INTERACTS WITH JUNB AND IRF4 TO REGULATE GENE EXPRESSION AND ILLUMINATED SEVERAL OTHER NOVEL TARGETS FOR FURTHER INVESTIGATION. 2023 5 5918 25 TARGETING BMI-1 IN B CELLS RESTORES EFFECTIVE HUMORAL IMMUNE RESPONSES AND CONTROLS CHRONIC VIRAL INFECTION. INEFFECTIVE ANTIBODY-MEDIATED RESPONSES ARE A KEY CHARACTERISTIC OF CHRONIC VIRAL INFECTION. HOWEVER, OUR UNDERSTANDING OF THE INTRINSIC MECHANISMS THAT DRIVE THIS DYSREGULATION ARE UNCLEAR. HERE, WE IDENTIFY THAT TARGETING THE EPIGENETIC MODIFIER BMI-1 IN MICE IMPROVES HUMORAL RESPONSES TO CHRONIC LYMPHOCYTIC CHORIOMENINGITIS VIRUS. BMI-1 WAS UPREGULATED BY GERMINAL CENTER B CELLS IN CHRONIC VIRAL INFECTION, CORRELATING WITH CHANGES TO THE ACCESSIBLE CHROMATIN LANDSCAPE, COMPARED TO ACUTE INFECTION. B CELL-INTRINSIC DELETION OF BMI1 ACCELERATED VIRAL CLEARANCE, REDUCED SPLENOMEGALY AND RESTORED SPLENIC ARCHITECTURE. DELETION OF BMI1 RESTORED C-MYC EXPRESSION IN B CELLS, CONCOMITANT WITH IMPROVED QUALITY OF ANTIBODY AND COUPLED WITH REDUCED ANTIBODY-SECRETING CELL NUMBERS. SPECIFICALLY, BMI-1-DEFICIENCY INDUCED ANTIBODY WITH INCREASED NEUTRALIZING CAPACITY AND ENHANCED ANTIBODY-DEPENDENT EFFECTOR FUNCTION. USING A SMALL MOLECULE INHIBITOR TO MURINE BMI-1, WE COULD DEPLETE ANTIBODY-SECRETING CELLS AND PROHIBIT DETRIMENTAL IMMUNE COMPLEX FORMATION IN VIVO. THIS STUDY DEFINES BMI-1 AS A CRUCIAL IMMUNE MODIFIER THAT CONTROLS ANTIBODY-MEDIATED RESPONSES IN CHRONIC INFECTION. 2022 6 1806 32 EFFECT OF TRANSCRIPTION INHIBITION AND GENERATION OF SUPPRESSIVE VIRAL NON-CODING RNAS. BACKGROUND: HIV-1 PATIENTS RECEIVING COMBINATION ANTIRETROVIRAL THERAPY (CART) SURVIVE INFECTION BUT REQUIRE LIFE-LONG ADHERENCE AT HIGH EXPENSE. IN CHRONIC CART-TREATED PATIENTS WITH UNDETECTABLE VIRAL TITERS, CELL-ASSOCIATED VIRAL RNA IS STILL DETECTABLE, POINTING TO LOW-LEVEL VIRAL TRANSCRIPTIONAL LEAKINESS. TO DATE, THERE ARE NO FDA-APPROVED DRUGS AGAINST HIV-1 TRANSCRIPTION. WE HAVE PREVIOUSLY SHOWN THAT F07#13, A THIRD GENERATION TAT PEPTIDE MIMETIC WITH COMPETITIVE ACTIVITY AGAINST CDK9/T1-TAT BINDING SITES, INHIBITS HIV-1 TRANSCRIPTION IN VITRO AND IN VIVO. RESULTS: HERE, WE DEMONSTRATE THAT INCREASING CONCENTRATIONS OF F07#13 (0.01, 0.1, 1 MICROM) CAUSE A DECREASE IN TAT LEVELS IN A DOSE-DEPENDENT MANNER BY INHIBITING THE CDK9/T1-TAT COMPLEX FORMATION AND SUBSEQUENT UBIQUITIN-MEDIATED TAT SEQUESTRATION AND DEGRADATION. OUR DATA INDICATE THAT COMPLEXES I AND IV CONTAIN DISTINCT PATTERNS OF UBIQUITINATED TAT AND THAT TRANSCRIPTIONAL INHIBITION INDUCED BY F07#13 CAUSES AN OVERALL REDUCTION IN TAT LEVELS. THIS REDUCTION MAY BE TRIGGERED BY F07#13 BUT ULTIMATELY IS MEDIATED BY TAR-GAG VIRAL RNAS THAT BIND SUPPRESSIVE TRANSCRIPTION FACTORS (SIMILAR TO 7SK, NRON, HOTAIR, AND XIST LNCRNAS) TO ENHANCE TRANSCRIPTIONAL GENE SILENCING AND LATENCY. THESE RNAS COMPLEX WITH PRC2, SIN3A, AND CUL4B, RESULTING IN EPIGENETIC MODIFICATIONS. FINALLY, WE OBSERVED AN F07#13-MEDIATED DECREASE OF VIRAL BURDEN BY TARGETING THE R REGION OF THE LONG TERMINAL REPEAT (HIV-1 PROMOTER REGION, LTR), PROMOTING BOTH PAUSED POLYMERASES AND INCREASED EFFICIENCY OF CRISPR/CAS9 EDITING IN INFECTED CELLS. THIS IMPLIES THAT GENE EDITING MAY BE BEST PERFORMED UNDER A REPRESSED TRANSCRIPTIONAL STATE. CONCLUSIONS: COLLECTIVELY, OUR RESULTS INDICATE THAT F07#13, WHICH CAN TERMINATE RNA POLYMERASE II AT DISTINCT SITES, CAN GENERATE SCAFFOLD RNAS, WHICH MAY ASSEMBLE INTO SPECIFIC SETS OF "RNA MACHINES" THAT CONTRIBUTE TO GENE REGULATION. IT REMAINS TO BE SEEN WHETHER THESE EFFECTS CAN ALSO BE SEEN IN VARIOUS CLADES THAT HAVE VARYING PROMOTER STRENGTH, MUTANT LTRS, AND IN PATIENT SAMPLES. 2019 7 5101 28 POLYCOMB FACTOR PHF19 CONTROLS CELL GROWTH AND DIFFERENTIATION TOWARD ERYTHROID PATHWAY IN CHRONIC MYELOID LEUKEMIA CELLS. POLYCOMB GROUP (PCG) OF PROTEINS ARE A GROUP OF HIGHLY CONSERVED EPIGENETIC REGULATORS INVOLVED IN MANY BIOLOGICAL FUNCTIONS, SUCH AS EMBRYONIC DEVELOPMENT, CELL PROLIFERATION, AND ADULT STEM CELL DETERMINATION. PHD FINGER PROTEIN 19 (PHF19) IS AN ASSOCIATED FACTOR OF POLYCOMB REPRESSOR COMPLEX 2 (PRC2), OFTEN UPREGULATED IN HUMAN CANCERS. IN PARTICULAR, MYELOID LEUKEMIA CELL LINES SHOW INCREASED LEVELS OF PHF19, YET LITTLE IS KNOWN ABOUT ITS FUNCTION. HERE, WE HAVE CHARACTERIZED THE ROLE OF PHF19 IN MYELOID LEUKEMIA CELLS. WE DEMONSTRATED THAT PHF19 DEPLETION DECREASES CELL PROLIFERATION AND PROMOTES CHRONIC MYELOID LEUKEMIA (CML) DIFFERENTIATION. MECHANISTICALLY, WE HAVE SHOWN HOW PHF19 REGULATES THE PROLIFERATION OF CML THROUGH A DIRECT REGULATION OF THE CELL CYCLE INHIBITOR P21. FURTHERMORE, WE OBSERVED THAT MTF2, A PHF19 HOMOLOG, PARTIALLY COMPENSATES FOR PHF19 DEPLETION IN A SUBSET OF TARGET GENES, INSTRUCTING SPECIFIC ERYTHROID DIFFERENTIATION. TAKEN TOGETHER, OUR RESULTS SHOW THAT PHF19 IS A KEY TRANSCRIPTIONAL REGULATOR FOR CELL FATE DETERMINATION AND COULD BE A POTENTIAL THERAPEUTIC TARGET FOR MYELOID LEUKEMIA TREATMENT. 2021 8 272 34 AGE-DEPENDENT DECREASE IN THE INDUCTION OF REGULATORY T CELLS IS ASSOCIATED WITH DECREASED EXPRESSION OF RALDH2 IN MESENTERIC LYMPH NODE DENDRITIC CELLS. A DECLINE IN IMMUNE FUNCTION WITH AGING HAS BEEN REPORTED. REGULATORY T CELL (TREG) INDUCTION IS KNOWN TO DECREASE WITH AGE, AND ELUCIDATING THE UNDERLYING MECHANISM IS IMPORTANT FOR PREVENTING AGE-RELATED DISEASES DUE TO AGE-RELATED CHRONIC INFLAMMATION. IN THE INTESTINE, DENDRITIC CELLS (DCS) PLAY AN IMPORTANT ROLE IN INDUCING TREGS SPECIFIC TO ORAL ANTIGENS, AND THEY EFFICIENTLY INDUCE TREGS VIA PRODUCTION OF RETINOIC ACID (RA), A VITAMIN A METABOLITE, CATALYZED BY THE ENZYME RETINALDEHYDE DEHYDROGENASE 2 (RALDH2). WE HAVE PREVIOUSLY REPORTED THAT IN THE MESENTERIC LYMPH NODE (MLN), A SECONDARY LYMPHOID TISSUE IN WHICH IMMUNE RESPONSES TO ORAL ANTIGENS ARE INDUCED, FOUR DC SUBSETS EXPRESS DIFFERENT LEVELS OF CD11B, CD103, AND PD-L1, AND WE HAVE REPORTED THAT THE CD11B(-)CD103(+)PD-L1(HIGH) SUBSET EXPRESSES THE HIGHEST LEVELS OF THE RALDH2 GENE AND INDUCES TREGS IN VITRO. WE EXAMINED TREG INDUCTION IN YOUNG AND AGED MICE USING A TREG INDUCTION MODEL BY ADMINISTERING A FOOD ANTIGEN, AND WE FOUND THAT ANTIGEN-SPECIFIC TREG INDUCTION WAS DECREASED IN AGED MICE. WE FURTHER INVESTIGATED THE MLN DCS, AND A SIGNIFICANT DECREASE IN RALDH2 GENE EXPRESSION WAS OBSERVED IN MLN DCS FROM AGED MICE. AS FACTORS, WE FOUND THAT THE PROPORTION OF THE CD11B(-)CD103(+)PD-L1(HIGH) SUBSET WAS DECREASED IN AGED MICE COMPARED WITH THAT IN YOUNG MICE AND THAT RALDH ENZYME ACTIVITY WAS DECREASED IN THE CD11B(-)CD103(+)PD-L1(HIGH) AND CD11B(+)CD103(+)PD-L1(HIGH) SUBSETS. FURTHERMORE, ANALYSIS OF THE METHYLATION OF THE RALDH2 GENE PROMOTER REGION REVEALED THAT CPG MOTIFS WERE MORE METHYLATED IN THE MLN DCS OF AGED MICE, SUGGESTING THAT RALDH2 EXPRESSION WAS SUPPRESSED BY EPIGENETIC CHANGES. FINALLY, WE FOUND THAT RA TREATMENT TENDED TO INCREASE TREG INDUCTION. THESE RESULTS SUGGEST THAT THE REGULATION OF RA PRODUCTION MAY BE INVOLVED IN THE AGE-RELATED DECREASE IN ANTIGEN-SPECIFIC TREG INDUCTION. 2020 9 2270 27 EPIGENETIC QUANTIFICATION OF IMMUNOSENESCENT CD8(+) TEMRA CELLS IN HUMAN BLOOD. AGE-RELATED CHANGES IN HUMAN T-CELL POPULATIONS ARE IMPORTANT CONTRIBUTORS TO IMMUNOSENESCENCE. IN PARTICULAR, TERMINALLY DIFFERENTIATED CD8(+) EFFECTOR MEMORY CD45RA(+) TEMRA CELLS AND THEIR SUBSETS HAVE CHARACTERISTICS OF CELLULAR SENESCENCE, ACCUMULATE IN OLDER INDIVIDUALS, AND ARE INCREASED IN AGE-RELATED CHRONIC INFLAMMATORY DISEASES. IN A DETAILED T-CELL PROFILING AMONG INDIVIDUALS OVER 65 YEARS OF AGE, WE FOUND A HIGH INTERINDIVIDUAL VARIATION AMONG CD8(+) TEMRA POPULATIONS. CD8(+) TEMRA PROPORTIONS CORRELATED POSITIVELY WITH CYTOMEGALOVIRUS (CMV) ANTIBODY LEVELS, HOWEVER, NOT WITH THE CHRONOLOGICAL AGE. IN THE ANALYSIS OF OVER 90 INFLAMMATION PROTEINS, WE IDENTIFIED PLASMA TRANCE/RANKL LEVELS TO ASSOCIATE WITH SEVERAL DIFFERENTIATED T-CELL POPULATIONS, INCLUDING CD8(+) TEMRA AND ITS CD28(-) SUBSETS. GIVEN THE STRONG POTENTIAL OF CD8(+) TEMRA CELLS AS A BIOMARKER FOR IMMUNOSENESCENCE, WE USED DEEP-AMPLICON BISULFITE SEQUENCING TO MATCH THEIR FREQUENCIES IN FLOW CYTOMETRY WITH CPG SITE METHYLATION LEVELS AND DEVELOPED A COMPUTATIONAL MODEL TO PREDICT CD8(+) TEMRA CELL PROPORTIONS FROM WHOLE BLOOD GENOMIC DNA. OUR FINDINGS CONFIRM THE ASSOCIATION OF CD8(+) TEMRA AND ITS SUBSETS WITH CMV INFECTION AND PROVIDE A NOVEL TOOL FOR THEIR HIGH THROUGHPUT EPIGENETIC QUANTIFICATION AS A BIOMARKER OF IMMUNOSENESCENCE. 2022 10 1334 26 DEREGULATION OF AIOLOS EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH EPIGENETIC MODIFICATIONS. CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS CHARACTERIZED BY A CLONAL ACCUMULATION OF MATURE NEOPLASTIC B CELLS THAT ARE RESISTANT TO APOPTOSIS. AIOLOS, A MEMBER OF THE IKAROS FAMILY OF ZINC-FINGER TRANSCRIPTION FACTORS, PLAYS AN IMPORTANT ROLE IN THE CONTROL OF MATURE B LYMPHOCYTE DIFFERENTIATION AND MATURATION. IN THIS STUDY, WE SHOWED THAT AIOLOS EXPRESSION IS UP-REGULATED IN B-CLL CELLS. THIS OVEREXPRESSION DOES NOT IMPLICATE ISOFORM IMBALANCE OR DISTURB AIOLOS SUBCELLULAR LOCALIZATION. THE CHROMATIN STATUS AT THE AIOLOS PROMOTER IN CLL IS DEFINED BY THE DEMETHYLATION OF DNA AND AN ENRICHMENT OF EUCHROMATIN ASSOCIATED HISTONE MARKERS, SUCH AS THE DIMETHYLATION OF THE LYSINE 4 ON HISTONE H3. THESE EPIGENETIC MODIFICATIONS SHOULD ALLOW ITS UPSTREAM EFFECTORS, SUCH AS NUCLEAR FACTOR-KAPPAB, CONSTITUTIVELY ACTIVATED IN CLL, TO GAIN ACCESS TO PROMOTER, RESULTING UP-REGULATION OF AIOLOS. TO DETERMINE THE CONSEQUENCES OF AIOLOS DEREGULATION IN CLL, WE ANALYZED THE EFFECTS OF AIOLOS OVEREXPRESSION OR DOWN-REGULATION ON APOPTOSIS. AIOLOS IS INVOLVED IN CELL SURVIVAL BY REGULATING THE EXPRESSION OF SOME BCL-2 FAMILY MEMBERS. OUR RESULTS STRONGLY SUGGEST THAT AIOLOS DEREGULATION BY EPIGENETIC MODIFICATIONS MAY BE A HALLMARK OF CLL. 2011 11 4990 36 PD-1-CIS IL-2R AGONISM YIELDS BETTER EFFECTORS FROM STEM-LIKE CD8(+) T CELLS. EXPANSION AND DIFFERENTIATION OF ANTIGEN-EXPERIENCED PD-1(+)TCF-1(+) STEM-LIKE CD8(+) T CELLS INTO EFFECTOR CELLS IS CRITICAL FOR THE SUCCESS OF IMMUNOTHERAPIES BASED ON PD-1 BLOCKADE(1-4). HASHIMOTO ET AL. HAVE SHOWN THAT, IN CHRONIC INFECTIONS, ADMINISTRATION OF THE CYTOKINE INTERLEUKIN (IL)-2 TRIGGERS AN ALTERNATIVE DIFFERENTIATION PATH OF STEM-LIKE T CELLS TOWARDS A DISTINCT POPULATION OF 'BETTER EFFECTOR' CD8(+) T CELLS SIMILAR TO THOSE GENERATED IN AN ACUTE INFECTION(5). IL-2 BINDING TO THE IL-2 RECEPTOR ALPHA-CHAIN (CD25) WAS ESSENTIAL IN TRIGGERING THIS ALTERNATIVE DIFFERENTIATION PATH AND EXPANDING BETTER EFFECTORS WITH DISTINCT TRANSCRIPTIONAL AND EPIGENETIC PROFILES. HOWEVER, CONSTITUTIVE EXPRESSION OF CD25 ON REGULATORY T CELLS AND SOME ENDOTHELIAL CELLS ALSO CONTRIBUTES TO UNWANTED SYSTEMIC EFFECTS FROM IL-2 THERAPY. THEREFORE, ENGINEERED IL-2 RECEPTOR BETA- AND GAMMA-CHAIN (IL-2RBETAGAMMA)-BIASED AGONISTS ARE CURRENTLY BEING DEVELOPED(6-10). HERE WE SHOW THAT IL-2RBETAGAMMA-BIASED AGONISTS ARE UNABLE TO PREFERENTIALLY EXPAND BETTER EFFECTOR T CELLS IN CANCER MODELS AND DESCRIBE PD1-IL2V, A NEW IMMUNOCYTOKINE THAT OVERCOMES THE NEED FOR CD25 BINDING BY DOCKING IN CIS TO PD-1. CIS BINDING OF PD1-IL2V TO PD-1 AND IL-2RBETAGAMMA ON THE SAME CELL RECOVERS THE ABILITY TO DIFFERENTIATE STEM-LIKE CD8(+) T CELLS INTO BETTER EFFECTORS IN THE ABSENCE OF CD25 BINDING IN BOTH CHRONIC INFECTION AND CANCER MODELS AND PROVIDES SUPERIOR EFFICACY. BY CONTRAST, PD-1- OR PD-L1-BLOCKING ANTIBODIES ALONE, OR THEIR COMBINATION WITH CLINICALLY RELEVANT DOSES OF NON-PD-1-TARGETED IL2V, CANNOT EXPAND THIS UNIQUE SUBSET OF BETTER EFFECTOR T CELLS AND INSTEAD LEAD TO THE ACCUMULATION OF TERMINALLY DIFFERENTIATED, EXHAUSTED T CELLS. THESE FINDINGS PROVIDE THE BASIS FOR THE DEVELOPMENT OF A NEW GENERATION OF PD-1 CIS-TARGETED IL-2R AGONISTS WITH ENHANCED THERAPEUTIC POTENTIAL FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS. 2022 12 4545 28 MUTANT P53 GAIN OF FUNCTION AND CHEMORESISTANCE: THE ROLE OF MUTANT P53 IN RESPONSE TO CLINICAL CHEMOTHERAPY. PURPOSE: TO REVIEW MECHANISMS UNDERLYING MUTANT P53 (MUTP53) GAIN OF FUNCTION (GOF) AND MUTP53-INDUCED CHEMORESISTANCE, AND TO INVESTIGATE THE ROLE OF MUTP53 IN RESPONSE TO CLINICAL CHEMOTHERAPY. METHODS: WE SEARCHED THE PUBMED DATABASE FOR CLINICAL STUDIES FROM THE PAST DECADE, INCLUDING DATA EVALUATING THE IMPACT OF MUTP53 IN CLINICAL CHEMOTHERAPY RESPONSE. RESULTS: INTERACTIONS BETWEEN MUTP53 AND TRANSCRIPTIONAL FACTORS, PROTEINS OR DNA STRUCTURES, AS WELL AS EPIGENETIC REGULATION, CONTRIBUTE TO MUTP53 GOF. MAJOR MECHANISMS OF MUTP53-INDUCED CHEMORESISTANCE INCLUDE ENHANCED DRUG EFFLUX AND METABOLISM, PROMOTING SURVIVAL, INHIBITING APOPTOSIS, UPREGULATING DNA REPAIR, SUPPRESSING AUTOPHAGY, ELEVATING MICROENVIRONMENTAL RESISTANCE AND INDUCING A STEM-LIKE PHENOTYPE. CLINICALLY, MUTP53 PREDICTED RESISTANCE TO CHEMOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA, AND ESOPHAGEAL AND OROPHARYNGEAL CANCERS, BUT ITS IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA WAS UNCLEAR. IN BLADDER CANCER, MUTP53 DID NOT PREDICT RESISTANCE, WHEREAS IN SOME BREAST AND OVARIAN CANCERS, IT WAS ASSOCIATED WITH SENSITIVITY TO CERTAIN CHEMOTHERAPEUTIC AGENTS. CONCLUSION: MUTP53 HAS AN INTRICATE ROLE IN THE RESPONSE TO CLINICAL CHEMOTHERAPY AND SHOULD NOT BE INTERPRETED IN ISOLATION. FURTHERMORE, WHEN PREDICTING TUMOR RESPONSE TO CHEMOTHERAPY BASED ON THE P53 STATUS, THE DRUGS USED SHOULD ALSO BE TAKEN INTO CONSIDERATION. THESE CONCEPTS REQUIRE FURTHER INVESTIGATION. 2017 13 102 19 A REGULATORY ROLE FOR CHD2 IN MYELOPOIESIS. THE TRANSCRIPTIONAL PROGRAM THAT DICTATES HAEMATOPOIETIC CELL FATE AND DIFFERENTIATION REQUIRES AN EPIGENETIC REGULATORY AND MEMORY FUNCTION, PROVIDED BY A NETWORK OF EPIGENETIC FACTORS THAT REGULATE DNA METHYLATION, POST-TRANSLATIONAL HISTONE MODIFICATIONS AND CHROMATIN STRUCTURE. DISTURBED EPIGENETIC REGULATION CAUSES PERTURBATIONS IN THE BLOOD CELL DIFFERENTIATION PROGRAM THAT RESULTS IN VARIOUS TYPES OF HAEMATOPOIETIC DISORDERS. THUS, ACCURATE EPIGENETIC REGULATION IS ESSENTIAL FOR FUNCTIONAL HAEMATOPOIESIS. IN THIS STUDY, WE USED A CRISPR-CAS9 SCREENING APPROACH TO IDENTIFY NEW EPIGENETIC REGULATORS IN MYELOID DIFFERENTIATION. WE DESIGNED A CHROMATIN-UMI CRISPR GUIDE LIBRARY TARGETING 1092 EPIGENETIC REGULATORS. PHORBOL 12-MYRISTATE 13-ACETATE (PMA) TREATMENT OF THE CHRONIC MYELOID LEUKAEMIA CELL LINE K-562 WAS USED AS A MEGAKARYOCYTIC MYELOID DIFFERENTIATION MODEL. BOTH PREVIOUSLY DESCRIBED DEVELOPMENTAL EPIGENETIC REGULATORS AND NOVEL FACTORS WERE IDENTIFIED IN OUR SCREEN. IN THIS STUDY, WE VALIDATED AND CHARACTERIZED A ROLE FOR THE CHROMATIN REMODELLER CHD2 IN MYELOID PROLIFERATION AND MEGAKARYOCYTIC DIFFERENTIATION. 2020 14 6055 27 THE CXXC1 SUBUNIT OF THE TRITHORAX COMPLEX DIRECTS EPIGENETIC LICENSING OF CD4+ T CELL DIFFERENTIATION. DIFFERENT DYNAMICS OF GENE EXPRESSION ARE OBSERVED DURING CELL DIFFERENTIATION. IN T CELLS, GENES THAT ARE TURNED ON EARLY OR TURNED OFF AND STAY OFF HAVE BEEN THOROUGHLY STUDIED. HOWEVER, GENES THAT ARE INITIALLY TURNED OFF BUT THEN TURNED ON AGAIN AFTER STIMULATION HAS CEASED HAVE NOT BEEN DEFINED; THEY ARE OBVIOUSLY IMPORTANT, ESPECIALLY IN THE CONTEXT OF ACUTE VERSUS CHRONIC INFLAMMATION. USING THE TH1/TH2 DIFFERENTIATION PARADIGM, WE FOUND THAT THE CXXC1 SUBUNIT OF THE TRITHORAX COMPLEX DIRECTS TRANSCRIPTION OF GENES INITIALLY DOWN-REGULATED BY TCR STIMULATION BUT UP-REGULATED AGAIN IN A LATER PHASE. THE LATE UP-REGULATION OF THESE GENES WAS IMPAIRED EITHER BY PROLONGED TCR STIMULATION OR CXXC1 DEFICIENCY, WHICH LED TO DECREASED EXPRESSION OF TRIB3 AND KLF2 IN TH1 AND TH2 CELLS, RESPECTIVELY. LOSS OF CXXC1 RESULTED IN ENHANCED PATHOGENICITY IN ALLERGIC AIRWAY INFLAMMATION IN VIVO. THUS, CXXC1 PLAYS ESSENTIAL ROLES IN THE ESTABLISHMENT OF A PROPER CD4+ T CELL IMMUNE SYSTEM VIA EPIGENETIC CONTROL OF A SPECIFIC SET OF GENES. 2021 15 5788 34 SREBP1 DRIVES KERATIN-80-DEPENDENT CYTOSKELETAL CHANGES AND INVASIVE BEHAVIOR IN ENDOCRINE-RESISTANT ERALPHA BREAST CANCER. APPROXIMATELY 30% OF ERALPHA BREAST CANCER PATIENTS RELAPSE WITH METASTATIC DISEASE FOLLOWING ADJUVANT ENDOCRINE THERAPIES. THE CONNECTION BETWEEN ACQUISITION OF DRUG RESISTANCE AND INVASIVE POTENTIAL IS POORLY UNDERSTOOD. IN THIS STUDY, WE DEMONSTRATE THAT THE TYPE II KERATIN TOPOLOGICAL ASSOCIATING DOMAIN UNDERGOES EPIGENETIC REPROGRAMMING IN AROMATASE INHIBITORS (AI)-RESISTANT CELLS, LEADING TO KERATIN-80 (KRT80) UPREGULATION. KRT80 EXPRESSION IS DRIVEN BY DE NOVO ENHANCER ACTIVATION BY STEROL REGULATORY ELEMENT-BINDING PROTEIN 1 (SREBP1). KRT80 UPREGULATION DIRECTLY PROMOTES CYTOSKELETAL REARRANGEMENTS AT THE LEADING EDGE, INCREASED FOCAL ADHESION AND CELLULAR STIFFENING, COLLECTIVELY PROMOTING CANCER CELL INVASION. SHEARWAVE ELASTICITY IMAGING PERFORMED ON PROSPECTIVELY RECRUITED PATIENTS CONFIRMS KRT80 LEVELS CORRELATE WITH STIFFER TUMORS. IMMUNOHISTOCHEMISTRY SHOWED INCREASED KRT80-POSITIVE CELLS AT RELAPSE AND, USING SEVERAL CLINICAL ENDPOINTS, KRT80 EXPRESSION ASSOCIATES WITH POOR SURVIVAL. COLLECTIVELY, OUR DATA UNCOVER AN UNPREDICTED AND POTENTIALLY TARGETABLE DIRECT LINK BETWEEN EPIGENETIC AND CYTOSKELETAL REPROGRAMMING PROMOTING CELL INVASION IN RESPONSE TO CHRONIC AI TREATMENT. 2019 16 942 34 CHRONIC LYMPHOCYTIC LEUKEMIA PRESENCE IMPAIRS ANTIGEN-SPECIFIC CD8(+) T-CELL RESPONSES THROUGH EPIGENETIC REPROGRAMMING TOWARDS SHORT-LIVED EFFECTORS. T-CELL DYSREGULATION IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ASSOCIATES WITH LOW RESPONSE RATES TO AUTOLOGOUS T CELL-BASED THERAPIES. HOW CLL AFFECTS ANTIGEN-SPECIFIC T-CELL RESPONSES REMAINS LARGELY UNKNOWN. WE INVESTIGATED (EPI)GENETIC AND FUNCTIONAL CONSEQUENCES OF ANTIGEN-SPECIFIC T-CELL RESPONSES IN PRESENCE OF CLL IN VITRO AND IN AN ADOPTIVE-TRANSFER MURINE MODEL. ALREADY AT STEADY-STATE, ANTIGEN-EXPERIENCED PATIENT-DERIVED T CELLS WERE SKEWED TOWARDS SHORT-LIVED EFFECTOR CELLS (SLEC) AT THE EXPENSE OF MEMORY-PRECURSOR EFFECTOR CELLS (MPEC). STIMULATION OF THESE T CELLS IN VITRO SHOWED RAPID INDUCTION OF EFFECTOR GENES AND SUPPRESSION OF KEY MEMORY TRANSCRIPTION FACTORS ONLY IN PRESENCE OF CLL CELLS, INDICATING EPIGENETIC REGULATION. THIS WAS INVESTIGATED IN VIVO BY FOLLOWING ANTIGEN-SPECIFIC RESPONSES OF NAIVE OT-I CD8(+) CELLS TO MCMV-OVA IN PRESENCE/ABSENCE OF TCL1 B-CELL LEUKEMIA. PRESENCE OF LEUKEMIA RESULTED IN INCREASED SLEC FORMATION, WITH DISTURBED INFLAMMATORY CYTOKINE PRODUCTION. CHROMATIN AND TRANSCRIPTOME PROFILING REVEALED STRONG EPIGENETIC MODIFICATIONS, LEADING TO ACTIVATION OF AN EFFECTOR AND SILENCING OF A MEMORY PROFILE THROUGH PRESENCE OF CLL CELLS. SECONDARY CHALLENGE IN VIVO CONFIRMED DYSFUNCTIONAL MEMORY RESPONSES BY ANTIGEN-EXPERIENCED OT-I CELLS GENERATED IN PRESENCE OF CLL. ALTOGETHER, WE SHOW THAT PRESENCE OF CLL INDUCES A SHORT-LIVED EFFECTOR PHENOTYPE AND IMPAIRED MEMORY RESPONSES BY EPIGENETIC REPROGRAMMING DURING PRIMARY RESPONSES. 2023 17 1966 25 EPIGENETIC ALTERATION OF PRKCDBP IN COLORECTAL CANCERS AND ITS IMPLICATION IN TUMOR CELL RESISTANCE TO TNFALPHA-INDUCED APOPTOSIS. PURPOSE: PRKCDBP IS A PUTATIVE TUMOR SUPPRESSOR IN WHICH ALTERATION HAS BEEN OBSERVED IN SEVERAL HUMAN CANCERS. WE INVESTIGATED EXPRESSION AND FUNCTION OF PRKCDBP IN COLORECTAL CELLS AND TISSUES TO EXPLORE ITS CANDIDACY AS A SUPPRESSOR IN COLORECTAL TUMORIGENESIS. EXPERIMENTAL DESIGN: EXPRESSION AND METHYLATION STATUS OF PRKCDBP AND ITS EFFECT ON TUMOR GROWTH WERE EVALUATED. TRANSCRIPTIONAL REGULATION BY NF-KAPPAB SIGNALING WAS DEFINED BY LUCIFERASE REPORTER AND CHROMATIN IMMUNOPRECIPITATION ASSAYS. RESULTS: PRKCDBP EXPRESSION WAS HARDLY DETECTABLE IN 29 OF 80 (36%) PRIMARY TUMORS AND 11 OF 19 (58%) CELL LINES, AND ITS ALTERATION CORRELATED WITH TUMOR STAGE AND GRADE. PROMOTER HYPERMETHYLATION WAS COMMONLY FOUND IN CANCERS. PRKCDBP EXPRESSION INDUCED THE G(1) CELL-CYCLE ARREST AND INCREASED CELLULAR SENSITIVITY TO VARIOUS APOPTOTIC STRESSES. PRKCDBP WAS INDUCED BY TNFALPHA, AND ITS LEVEL CORRELATED WITH TUMOR CELL SENSITIVITY TO TNFALPHA-INDUCED APOPTOSIS. PRKCDBP INDUCTION BY TNFALPHA WAS DISRUPTED BY BLOCKING NF-KAPPAB SIGNALING WHILE IT WAS ENHANCED BY RELA TRANSFECTION. THE PRKCDBP PROMOTER ACTIVITY WAS INCREASED IN RESPONSE TO TNFALPHA, AND THIS RESPONSE WAS ABOLISHED BY DISRUPTION OF A KAPPAB SITE IN THE PROMOTER. PRKCDBP DELAYED THE FORMATION AND GROWTH OF XENOGRAFT TUMORS AND IMPROVED TUMOR RESPONSE TO TNFALPHA-INDUCED APOPTOSIS. CONCLUSIONS: PRKCDBP IS A PROAPOPTOTIC TUMOR SUPPRESSOR WHICH IS COMMONLY ALTERED IN COLORECTAL CANCER BY PROMOTER HYPERMETHYLATION, AND ITS GENE TRANSCRIPTION IS DIRECTLY ACTIVATED BY NF-KAPPAB IN RESPONSE TO TNFALPHA. THIS SUGGESTS THAT PRKCDBP INACTIVATION MAY CONTRIBUTE TO TUMOR PROGRESSION BY REDUCING CELLULAR SENSITIVITY TO TNFALPHA AND OTHER STRESSES, PARTICULARLY UNDER CHRONIC INFLAMMATORY MICROENVIRONMENT. 2011 18 6709 33 VIRAL TRANSDUCTION OF PRIMARY HUMAN LYMPHOMA B CELLS REVEALS MECHANISMS OF NOTCH-MEDIATED IMMUNE ESCAPE. HOTSPOT MUTATIONS IN THE PEST-DOMAIN OF NOTCH1 AND NOTCH2 ARE RECURRENTLY IDENTIFIED IN B CELL MALIGNANCIES. TO ADDRESS HOW NOTCH-MUTATIONS CONTRIBUTE TO A DISMAL PROGNOSIS, WE HAVE GENERATED ISOGENIC PRIMARY HUMAN TUMOR CELLS FROM PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL), DIFFERING ONLY IN THEIR EXPRESSION OF THE INTRACELLULAR DOMAIN (ICD) OF NOTCH1 OR NOTCH2. OUR DATA DEMONSTRATE THAT BOTH NOTCH-PARALOGS FACILITATE IMMUNE-ESCAPE OF MALIGNANT B CELLS BY UP-REGULATING PD-L1, PARTLY DEPENDENT ON AUTOCRINE INTERFERON-GAMMA SIGNALING. IN ADDITION, NOTCH-ACTIVATION CAUSES SILENCING OF THE ENTIRE HLA-CLASS II LOCUS VIA EPIGENETIC REGULATION OF THE TRANSCRIPTIONAL CO-ACTIVATOR CIITA. NOTABLY, WHILE NOTCH1 AND NOTCH2 GOVERN SIMILAR TRANSCRIPTIONAL PROGRAMS, DISEASE-SPECIFIC DIFFERENCES IN THEIR EXPRESSION LEVELS CAN FAVOR PARALOG-SPECIFIC SELECTION. IMPORTANTLY, NOTCH-ICD ALSO STRONGLY DOWN-REGULATES THE EXPRESSION OF CD19, POSSIBLY LIMITING THE EFFECTIVENESS OF IMMUNE-THERAPIES. THESE NOTCH-MEDIATED IMMUNE ESCAPE MECHANISMS ARE ASSOCIATED WITH THE EXPANSION OF EXHAUSTED CD8(+) T CELLS IN VIVO. 2022 19 5153 27 PPP2R2B HYPERMETHYLATION CAUSES ACQUIRED APOPTOSIS DEFICIENCY IN SYSTEMIC AUTOIMMUNE DISEASES. CHRONIC INFLAMMATION CAUSES TARGET ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES. THE FACTORS THAT ALLOW THIS PROTRACTED RESPONSE ARE POORLY UNDERSTOOD. WE ANALYZED THE TRANSCRIPTIONAL REGULATION OF PPP2R2B (B55SS), A MOLECULE NECESSARY FOR THE TERMINATION OF THE IMMUNE RESPONSE, IN PATIENTS WITH AUTOIMMUNE DISEASES. ALTERED EXPRESSION OF B55SS CONDITIONED RESISTANCE TO CYTOKINE WITHDRAWAL-INDUCED DEATH (CWID) IN PATIENTS WITH AUTOIMMUNE DISEASES. THE IMPAIRED UPREGULATION OF B55SS WAS CAUSED BY INFLAMMATION-DRIVEN HYPERMETHYLATION OF SPECIFIC CYTOSINES LOCATED WITHIN A REGULATORY ELEMENT OF PPP2R2B PREVENTING CTCF BINDING. THIS PHENOTYPE COULD BE INDUCED IN HEALTHY T CELLS BY EXPOSURE TO TNF-ALPHA. OUR RESULTS REVEAL A GENE WHOSE EXPRESSION IS AFFECTED BY AN ACQUIRED DEFECT, THROUGH AN EPIGENETIC MECHANISM, IN THE SETTING OF SYSTEMIC AUTOIMMUNITY. BECAUSE FAILURE TO REMOVE ACTIVATED T CELLS THROUGH CWID COULD CONTRIBUTE TO AUTOIMMUNE PATHOLOGY, THIS MECHANISM ILLUSTRATES A VICIOUS CYCLE THROUGH WHICH AUTOIMMUNE INFLAMMATION CONTRIBUTES TO ITS OWN PERPETUATION. 2019 20 3948 31 LNCRNA-CD160 DECREASES THE IMMUNITY OF CD8(+) T CELLS THROUGH EPIGENETIC MECHANISMS IN HEPATITIS B VIRUS INFECTION. THE TRANSFER AND DEVELOPMENT OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IS ASSOCIATED WITH THE T CELL IMMUNE RESPONSE, THEREFORE INVESTIGATING THE KEY REGULATORS OF CELL IMMUNE RESPONSE IS NEEDED TO IMPROVE CHRONIC HBV TREATMENT. BLOOD SAMPLES FROM PATIENTS WITH CHRONIC HBV INFECTION WERE USED TO CONFIRM THE CORRELATION BETWEEN HBV INFECTION STAGE AND CD160 RECEPTOR EXPRESSION LEVELS IN CD8(+) T CELLS, THE CD8(+) T CELLS ARE USED TO RESEARCH THE MECHANISM OF T CELL IMMUNE RESPONSE MODULATION, MOREOVER, C3H/HEN MICE WITH REDUCED CD160 EXPRESSION LEVELS WERE USED TO INVESTIGATE THE ASSOCIATION BETWEEN LONG NON-CODING (LNC)RNA-CD160 AND HBV INFECTION. LONG NON-CODING (LNC)RNA-CD160 AND HISTONE-MODIFICATION ENZYME GENE HISTONE DEACETYLASE 11 (HDAC11) EXPRESSION LEVELS WERE NEGATIVELY ASSOCIATED WITH CD160 EXPRESSION. LNCRNA-CD160 CAN INHIBIT THE SECRETION OF IFN-GAMMA AND TNF-ALPHA THROUGH HDAC11 RECRUITMENT AND BIND TO HDAC11 TO FORM A COMPLEX ON THE PROMOTERS OF IFN-GAMMA AND TNF-ALPHA. THE HDAC11, IFN-GAMMA AND TNF-ALPHA FORM A COMPLEX AND ENHANCE THE METHYLATION OF H3K9ME1, CHROMATIN CHANGES INTO THE HETEROCHROMATIN AND THE TRANSCRIPTION OF IFN-GAMMA AND TNF-ALPHA IS BLOCKED; MOREOVER, THE HDAC11/IFN-GAMMA/TNF-ALPHA COMPLEX CAN ALSO INHIBIT THE SECRETION OF IFN-GAMMA AND TNF-ALPHA IN CD160(-) CD8(+) T CELLS AND SUPPRESSES THE FUNCTION OF CD8(+) T CELLS. FURTHERMORE, SMALL INTERFERING RNA TARGETING LNCRNA-CD160 CAN BLOCK HBV INFECTION PROGRESSION. LNCRNA-CD160 ACTS AS AN IMMUNE SUPPRESSIVE FACTOR AND IS EXPRESSED AT A HIGH LEVEL IN PERIPHERAL BLOOD CD8(+) T CELLS OF HBV INFECTED PATIENTS. FURTHERMORE, HIGH EXPRESSION LEVELS OF LNCRNA-CD160 CAN CONTRIBUTE TO THE INHIBITION OF IFN-GAMMA AND TNF-ALPHA SECRETION IN CD8(+) T CELLS AND DECREASE THE IMMUNE RESPONSE OF CD8(+) T CELLS. THEREFORE, LNCRNA-CD160 MAY BECOME A NEW TARGET FOR IMMUNOTHERAPY OF CHRONIC HBV INFECTION IN THE FUTURE AND MAY PROVIDE A NEW THERAPEUTIC STRATEGY FOR THE TREATMENT OF HBV INFECTION. 2020